KWM Communications

Driven, passionate, and trusted C-level strategic communications advisors

[MarketWatch @MarketWatch]

Wall Street can’t stop talking about ‘MANGOS’ stocks as the ‘Magnificent Seven’ becomes passé https://t.co/FjQlEQuqjV

[Ligand @Ligand_LGND]

Today we announced an agreement to acquire @XOMARoyalty, expanding our royalty portfolio to over 200 assets and adding 7 commercial products. The transaction is expected to be immediately accretive to Ligand adjusted EPS and close in Q3’26. https://t.co/bOjuX5IwLU

[Barron's Advisor @barronsadvisor]

RWA Wealth’s Joseph Powers: How Investors Can Navigate the Fog of the Iran War https://t.co/ZUSNdSM9c8

[Michael Larkin @IBD_MLarkin]

This #Pharma #Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth. #StocksToBuy

https://t.co/ZXwuukzSST

[Yahoo Finance @YahooFinance]

Tera fab's "are really expensive and we don't have the infrastructure to build them here in the United States in the same way that Tesla is talking about," F.L. Putnam Investment Management Co. chief market strategist Ellen Hazen says.

[Boston Business Journal @BosBizJournal]

Heading into the 2026 J.P. Morgan Healthcare Conference, industry watchers are expecting the rise of China, the quantifiable benefits of AI, and the return of financings and M&A to be top of mind. https://t.co/AeBNe7w81a

[CNBC @CNBC]

Buy this global chipmaker over Nvidia as AI competition ramps up, F.L.Putnam strategist says https://t.co/8wRb3ZqijJ

[Investors.com @IBDinvestors]

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year
https://t.co/rmHICtgVFJ

[Citywire RIA @CitywireRIA]

$18bn RWA Wealth Partners returns to M&A market with Bay Area buy: https://t.co/yYI5n8MuWF

[Dermatology Times @DermTimesNow]

❗Pelthos Therapeutics announced it has launched berdazimer topical gel, 10.3% (Zelsuvmi), a first-in-class, nitric oxide-releasing gel approved for at-home application in adults and children aged 1 year and older.

https://t.co/fMWhykfnJI

[Pelthos Therapeutics @PelthosT]

Today we are proud to launch #ZELSUVMI. The product is now available by prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies. Learn more: https://t.co/DWCQNgKHjX

[Barron's Advisor @barronsadvisor]

RWA Wealth Partners’ Michelle Knight: From English Major to CEO of an $18 Billion Firm https://t.co/bsv9nBMOpx

[Nasdaq Exchange @NasdaqExchange]

@Ligand_LGND has been investing and advancing medicines since its inception. ⚕️

Get to know more about the #NasdaqListed company $LGND, from its defining moments to the future.

Click through below. ➡️

[Nasdaq Exchange @NasdaqExchange]

🔬 Advancing tomorrow’s medicines.

🌿 Biopharmaceutical company @Ligand_LGND invests in the groundbreaking medicines of today and tomorrow.

🥳 Today, Ligand celebrates its recent transaction with Channel Therapeutics to launch a new medication called ZELSUVMI!

[Yahoo Finance @YahooFinance]

"Everyone knows the deficit is running at six and a half to 7% of GDP," F.L.Putnam Investment Management strategist Ellen Hazen says on the equity and fixed income markets barely responding to Moody's downgrade. "Everyone knows that debt-to-GDP is pretty high and unsustainable."

[Ligand @Ligand_LGND]

Ligand subsidiary @PelthosT to merge with @ChromocellThera. The transaction will raise $50 million in equity capital, and the combined company will focus on commercializing ZELSUVMI™ for molluscum. Ligand is entitled to a 13% royalty on worldwide sales. https://t.co/pBnl7IWaCn

[Boston Business Journal @BosBizJournal]

F.L. Putnam, the Lynnfield-based investment management company whose New England roots date back a century, is expanding to Virginia with the acquisition of a registered investment advisor there. https://t.co/n1oLUJDNGL

[The Pharma Letter @ThePharmaLetter]

@Ligand_LGND invests $75 million in @CastleCreekBio's gene therapy https://t.co/GacEl6l8iS

[Ligand @Ligand_LGND]

Today we announced the closing of a $50mm commitment to lead a $75mm #royaltyfinancing in @CastleCreekBio to advance D-Fi, an orphan drug-designated gene therapy. Ligand acquired a mid-single digit royalty on worldwide sales of D-Fi. https://t.co/tr831lI8vn

[Yahoo Finance @YahooFinance]

“The cost of using AI is much lower than what we thought just a month or two ago,” F.L.Putnam Investment Management Co.’s Ellen Hazen says.

She explains how to be best positioned for the AI trade: